{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:26:39Z","timestamp":1768454799133,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1053\/j.seminhematol.2025.04.003","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:48:17Z","timestamp":1744148897000},"page":"120-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Report of Consensus Panel 6 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on Diagnosis and Management of Transformed Waldenstrom's Macroglobulinemia"],"prefix":"10.1053","volume":"62","author":[{"given":"Eric","family":"Durot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jithma P.","family":"Abeykoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Roos-Weil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalampia","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Auer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger G.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Dogliotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey V.","family":"Matous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Buske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1053\/j.seminhematol.2025.04.003_bib0001","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ajh.24477","article-title":"Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstr\u00f6m Macroglobulinemia","volume":"91","author":"Castillo","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.003_bib0002","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ajh.25697","article-title":"Impact of MYD88L265P mutation status on histological transformation of Waldenstr\u00f6m Macroglobulinemia","volume":"95","author":"Zanwar","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.003_bib0003","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41408-024-01194-5","article-title":"A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study","volume":"14","author":"Vaughn","year":"2024","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.04.003_bib0004","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.3324\/haematol.2020.262899","article-title":"A prognostic index predicting survival in transformed Waldenstr\u00f6m Macroglobulinemia","volume":"106","author":"Durot","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.003_bib0005","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1200\/JCO.2007.15.1530","article-title":"Increased incidence of transformation and myelodysplasia\/acute leukemia in patients with Waldenstr\u00f6m Macroglobulinemia treated with nucleoside analogs","volume":"27","author":"Leleu","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.003_bib0006","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2012.44.7920","article-title":"Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstr\u00f6m macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma","volume":"31","author":"Leblond","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.003_bib0007","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15049","article-title":"MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival","volume":"180","author":"Treon","year":"2018","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.04.003_bib0008","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/bloodadvances.2018022962","article-title":"Insights into the genomic landscape of MYD88 wild-type Waldenstr\u00f6m Macroglobulinemia","volume":"2","author":"Hunter","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.003_bib0009","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bjh.14881","article-title":"Transformed Waldenstr\u00f6m Macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)","volume":"179","author":"Durot","year":"2017","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.04.003_bib0010","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood.2022015520","article-title":"Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath Network Survey","volume":"140","author":"Syrykh","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.003_bib0011","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.04.003_bib0012","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.003_bib0013","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.04.003_bib0014","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ajh.22044","article-title":"The role of 18F-FDG PET\/CT imaging in Waldenstrom Macroglobulinemia","volume":"86","author":"Banwait","year":"2011","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.04.003_bib0015","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/bloodadvances.2022007331","article-title":"High frequency of central nervous system involvement in transformed Waldenstr\u00f6m Macroglobulinemia","volume":"6","author":"Durot","year":"2022","journal-title":"Blood Adv"},{"issue":"26","key":"10.1053\/j.seminhematol.2025.04.003_bib0016","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.003_bib0017","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjh.15610","article-title":"Genetic analysis of Diffuse large B-cell Lymphoma occurring in cases with antecedent Waldenstr\u00f6m Macroglobulinaemia reveals different patterns of clonal evolution","volume":"185","author":"Talaulikar","year":"2019","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.04.003_bib0018","doi-asserted-by":"crossref","first-page":"e976","DOI":"10.1097\/HS9.0000000000000976","article-title":"Clonal relationship and mutation analysis in lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia associated with diffuse large B-cell lymphoma","volume":"7","author":"Berendsen","year":"2023","journal-title":"Hemasphere"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.04.003_bib0019","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2025.04.003_bib0020","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of Ibrutinib and Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.003_bib0021","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood.2020006578","article-title":"A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma","volume":"137","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.003_bib0022","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.003_bib0023","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/bloodadvances.2020002982","article-title":"Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines","volume":"5","author":"Moccia","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.04.003_bib0024","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.3324\/haematol.2019.229948","article-title":"Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review","volume":"105","author":"Eyre","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.003_bib0025","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood.2021012888","article-title":"Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions","volume":"139","author":"Orellana-Noia","year":"2022","journal-title":"Blood."},{"issue":"7","key":"10.1053\/j.seminhematol.2025.04.003_bib0026","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ajh.26181","article-title":"Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma","volume":"96","author":"Puckrin","year":"2021","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.04.003_bib0027","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.3324\/haematol.2023.284281","article-title":"Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis","volume":"109","author":"Tolley","year":"2024","journal-title":"Haematologica"},{"issue":"16","key":"10.1053\/j.seminhematol.2025.04.003_bib0028","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2021014506","article-title":"Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients","volume":"139","author":"Wilson","year":"2022","journal-title":"Blood"},{"issue":"35","key":"10.1053\/j.seminhematol.2025.04.003_bib0029","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1200\/JCO.23.00365","article-title":"High-dose methotrexate as CNS prophylaxis in high-risk aggressive B-cell lymphoma","volume":"41","author":"Lewis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.04.003_bib0030","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/annonc\/mdy167","article-title":"ESMO Lymphoma Consensus Conference Panel members. ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients","volume":"29","author":"Hutchings","year":"2018","journal-title":"Ann Oncol."},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.003_bib0031","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bjh.16866","article-title":"The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology good practice paper","volume":"190","author":"McKay","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.003_bib0032","doi-asserted-by":"crossref","first-page":"E46","DOI":"10.1002\/ajh.27167","article-title":"Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: a detailed analysis of toxicity and impact on CNS relapse","volume":"99","author":"Wilson","year":"2024","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.04.003_bib0033","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.bbmt.2014.07.015","article-title":"Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma","volume":"20","author":"Villa","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.04.003_bib0034","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/annonc\/mdt029","article-title":"Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation","volume":"24","author":"Villa","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.003_bib0035","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12570","article-title":"Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database","volume":"163","author":"Ban-Hoefen","year":"2013","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.04.003_bib0036","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood-2015-01-622084","article-title":"Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12","volume":"126","author":"Kuruvilla","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.003_bib0037","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/bjh.17072","article-title":"Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study","volume":"191","author":"Chin","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.003_bib0038","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ajh.27543","article-title":"Autologous and allogeneic stem-cell transplantation for transformed Waldenstr\u00f6m Macroglobulinemia","volume":"100","author":"Durot","year":"2025","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.003_bib0039","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"ZUMA-7 investigators; Kite members. Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.04.003_bib0040","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.04.003_bib0041","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.003_bib0042","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.2024024526","article-title":"Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma","volume":"144","author":"Crochet","year":"2024","journal-title":"Blood."},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.003_bib0043","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/10428194.2019.1665668","article-title":"Chimeric antigen receptor T cells for treatment of transformed Waldenstr\u00f6m macroglobulinemia","volume":"61","author":"Bansal","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"10254","key":"10.1053\/j.seminhematol.2025.04.003_bib0044","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"10.1053\/j.seminhematol.2025.04.003_bib0045","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood.2024024452","article-title":"High efficacy of CD19 CAR T cells in patients with transformed Waldenstr\u00f6m Macroglobulinemia","volume":"143","author":"Durot","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.003_bib0046","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ajh.27548","article-title":"Outcomes of CD19 CAR T in transformed indolent lymphoma compared to de novo aggressive large B-cell lymphoma","volume":"100","author":"Thiruvengadam","year":"2025","journal-title":"Am J Hematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T13:22:37Z","timestamp":1750857757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0037196325000137"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.04.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Report of Consensus Panel 6 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on Diagnosis and Management of Transformed Waldenstrom's Macroglobulinemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}